The biopharmaceutical industry currently finds itself at a precarious intersection of unprecedented innovation and antiquated validation. We have unlocked unprecedented capabilities in gene editing and cell engineering, yet the fundamental mechanism we use to determine if a drug is safe for humans remains tethered to the past. The industry standard, animal testing, is costly, ethically fraught, and often fails to predict human biological responses.
Over 90 percent of drug candidates that successfully pass animal testing fail in human clinical trials. This staggering attrition rate highlights a fundamental gap in our preclinical validation processes; we are trying to cure human diseases using non-human proxies that simply cannot replicate our complex biology.
The solution lies in New Approach Methodologies (NAMs), specifically induced pluripotent stem cell (iPSC)-derived organoids, organ-on-a-chip platforms, and microphysiological systems. However, unlocking their potential requires us to move beyond bespoke science and embrace an industrialized, engineering-first approach.
The context for this shift has changed dramatically with the passing of the FDA Modernization Act 2.0 and 3.0, starting with the FDA’s announcement in April 2025 to phase out animal testing. This legislation was a watershed moment, explicitly authorizing the use of non-animal methods like organoids in regulatory submissions and removing the requirement for preclinical animal testing. The new framework theoretically presumes that animal models are not needed unless a specific justification proves they are. Most recently, the CDC instructed all researchers to end non-human primate testing by the end of 2025, and the FDA has issued a draft guidance to stop non-human primate testing for certain monoclonal antibodies.
However, the FDA has effectively told the industry to "jump" toward these new technologies without specifying where to land in many instances. By mandating the use of NAMs without establishing a transparent regulatory framework or providing the necessary funding, the FDA Modernization Act has left the industry in a state of high-risk uncertainty. Without defined acceptance criteria and a commitment to standardized model validation, investors and developers will continue to hesitate, delaying the infrastructure required to adopt organoids at scale.
The US, however, is not operating in a vacuum. As we grapple with this predictability gap, our international peers are moving with purpose. The UK has established a clear precedent with its "Accelerated Roadmap," dedicating £75 million in new funding specifically for the research, validation, and regulatory streamlining of NAMs.
Crucially, the UK is establishing the UK Centre for the Validation of Alternative Methods (UKCVAM) to serve as a strategic hub for this transition. They are prioritizing technologies that offer superior human physiological relevance, such as organoids and organ-on-a-chip platforms. This coordinated effort contrasts sharply with the fragmented approach currently seen in the US. The UK model demonstrates that government commitment can drive the creation of a "preclinical translational models hub" that de-risks adoption for the entire sector.
Even if the regulatory pathway were perfectly paved today, the industry would still be challenged with a standardization crisis. Reproducibility starts with starting materials, and currently, those materials are highly variable.
Organoid science has largely been the domain of non-standardized, academic expertise. Lab-specific protocols create massive variability, making it nearly impossible to compare data across organizations or even between operators in the same lab. We lack the fundamental "rulers" to measure our work; there are no globally accepted reference standards for cells, materials, or characterization methods. Without a common yardstick, results are meaningless in a regulatory context.
This issue is also acute with iPSCs, the foundational engine for an enormous regenerative medicine market. Most therapies and models are built on aging, unstable cells derived through clonal expansion. This traditional process of iPSC reprogramming and expansion creates a major bottleneck to their industrialization, forcing cells through stressful manipulations and clonal expansion leading to acquired genetic mutations and loss of function. Developers often lose years of time and millions of dollars trying to build therapies on this flawed foundation.
To overcome these hurdles, we must apply rigorous engineering principles to biology. We need "organoid-grade" cells that are standardized, well characterized, and manufacturing-ready at scale.
The first step is rethinking reprogramming. By utilizing an mRNA-based polyclonal reprogramming strategy, we can capture the genetic diversity of the donor without the bottleneck of clonal selection. This allows for the creation of Master Cell Banks (MCB) at much lower passage numbers (e.g., Passage 10) compared to conventional methods that push cells to Passage 30 or 40.. The result is a starting material that is genetically "younger," healthier, more stable, and that more closely resembles pluripotent cells found in the body.
The second leap in expertise involves high-density cell banking. In standard workflows, researchers must thaw a vial of cells and spend weeks expanding them in a "seed train" to generate sufficient cell numbers to begin organoid differentiation workflows. This not only adds months to the experimental timeline but introduces variability and ages cells with each passage. New industrial platforms now allow for the cryopreservation of suspension-adapted iPSCs at high densities. These Ready-to-DifferentiateTM (RTDTM)-iPSCs can be thawed and immediately cultured in 2D or 3D formats, generating thousands of uniform aggregates overnight. This seed train elimination ensures that every single differentiation starts from the exact same biological point, guaranteeing comparability for lab-to-lab and experiment-to-experiment analyses. This is not just a convenience; it is a requirement for regulatory acceptance. We are moving from bespoke science to a scalable, reproducible workflow that can be standardized and compared across the industry.
If we can solve the standardization crisis and close the regulatory predictability gap, the potential of organoid technology is limitless. We are moving toward a future of personalized medicine, where we can model an individual's biological responses before the first dose of a drug, cell therapy, or gene therapy is ever administered.
Imagine testing drug efficacy and toxicity on an organoid or organ-on-a-chip “avatar” derived from a specific patient. This capability would allow us to stratify patients for clinical trials, selecting only those most likely to respond, thereby increasing success rates and reducing the number of human subjects needed for testing. Furthermore, by using standardized iPSCs, we can generate libraries of organoids that represent national or global population diversity, ensuring that drugs are safe for all demographics, not just a select few.
Industry needs to take the lead on these cutting-edge technologies. This is why Pluristyx has formed the Organoid COMMONS, a public-private consortium working to establish the global standards and reference materials and methodologies the industry desperately needs. By pooling the expertise of industry leaders and working with regulators, we can hopefully validate these New Approach Methodologies once, rather than forcing every sponsor to reinvent the wheel, adding significant cost and time to therapeutic programs.
We have the mandate. We have the technology. Now, we must build the roadmap to achieve success. By combining standardized biological inputs with scalable engineering and a clear regulatory timeline, we can transform organoids from a promising experiment into the new standard for drug discovery. The tools are in our hands; it is time to industrialize them.